AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 13, 2024
(Valerii Apetroaiei/Getty Images) Exercise is great for improving heart health. But the thought of hitting the gym or going for a jog might put some people off from doing it. And, if you have a heart condition already, such dynamic exercises may not be safe to do.
JAMA Internal Medicine
OCTOBER 13, 2024
This multicenter randomized clinical trial investigates the efficacy and safety of acupuncture compared with sham acupuncture in patients with chronic sciatica from herniated disk.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 13, 2024
The Materiovigilance Programme of India (MvPI), under the Indian Pharmacopoeia Commission, has released the updated version of the medical devices adverse event reporting form, for the use of manufacturers, importers and distributors of medical devices and healthcare professionals.
JAMA Internal Medicine
OCTOBER 13, 2024
This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people with obesity and the benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
pharmaphorum
OCTOBER 13, 2024
Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year.Marstacimab will be launched as Hympavzi to treat haemophilia A without factor VIII inhibitors and haemophilia B without factor IX inhibitors in patients aged 12 and older and is the first drug in the anti-TFPI class to be approved in the US.
FDA Law Blog
OCTOBER 13, 2024
By Mark A. Tobolowsky — The Rare Pediatric Disease Priority Review Voucher program has had a bit of a tumultuous history in its 12 short years of existence. Designed to incentivize the development of drugs for pediatric rare diseases where such development may not otherwise have occurred, vouchers may be granted for drugs for serious or life-threatening rare diseases where the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years.
Expert insights. Personalized for you.
234 
Let's personalize your content